Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 2
2001 1
2003 12
2004 19
2005 16
2006 9
2007 12
2008 24
2009 16
2010 12
2011 9
2012 8
2013 9
2014 6
2015 4
2016 4
2017 2
2018 3
2019 4
2020 2
2021 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

174 results
Results by year
Filters applied: . Clear all
Page 1
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.
Song Y, Li X, Pavithra S, Li D. Song Y, et al. PLoS One. 2013 Nov 20;8(11):e78972. doi: 10.1371/journal.pone.0078972. eCollection 2013. PLoS One. 2013. PMID: 24278113 Free PMC article. Review.
BACKGROUND: Venous thromboembolism (VTE) is a prevalent disease with potential serious consequences. Idraparinux and idrabiotaparinux are two kinds of long-acting pentasaccharides. ...OBJECTIVE: To evaluate the effect of idraparinux or idrabiotaparinux versus other …
BACKGROUND: Venous thromboembolism (VTE) is a prevalent disease with potential serious consequences. Idraparinux and idrabiotaparinux …
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H, Akl EA. Kahale LA, et al. Cochrane Database Syst Rev. 2018 Jun 19;6(6):CD006650. doi: 10.1002/14651858.CD006650.pub5. Cochrane Database Syst Rev. 2018. PMID: 29920657 Free PMC article. Review.
The second study on DOAC versus LMWH was published as an abstract and is not included in the main analysis.Idraparinux versus vitamin K antagonistsOne RCT with 284 participants compared once-weekly subcutaneous injection of idraparinux versus standard treatment (par …
The second study on DOAC versus LMWH was published as an abstract and is not included in the main analysis.Idraparinux versus vitamin …
Idraparinux sodium: SANORG 34006, SR 34006.
[No authors listed] [No authors listed] Drugs R D. 2004;5(3):164-5. doi: 10.2165/00126839-200405030-00006. Drugs R D. 2004. PMID: 15139779 Review.
Idraparinux sodium [SANORG 34006, SR 34006], a synthetic, anti Xa pentasaccharide and analogue of SR 32701 and fondaparinux sodium, was in development with Sanofi (now Sanofi-Synthelabo) and Organon (Akzo Nobel) in Europe and the USA (now Sanofi-Synthe …
Idraparinux sodium [SANORG 34006, SR 34006], a synthetic, anti Xa pentasaccharide and analogue of SR 32701 and f …
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Herbert JM, et al. Blood. 1998 Jun 1;91(11):4197-205. Blood. 1998. PMID: 9596667 Free article.
SANORG 34006 is a new sulfated pentasaccharide obtained by chemical synthesis. ...In vitro, SANORG 34006 inhibited thrombin generation occurring via both the extrinsic and intrinsic pathway. ...
SANORG 34006 is a new sulfated pentasaccharide obtained by chemical synthesis. ...In vitro, SANORG 34006 inhibit …
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L. Prandoni P, et al. Expert Opin Investig Drugs. 2008 May;17(5):773-7. doi: 10.1517/13543784.17.5.773. Expert Opin Investig Drugs. 2008. PMID: 18447601 Review.
BACKGROUND: Idraparinux is a synthetic pentasaccharide that binds to antithrombin with high affinity. ...Finally, in patients with AF the long-term treatment with idraparinux was as effective as vitamin K antagonists, but caused more bleeding. ...
BACKGROUND: Idraparinux is a synthetic pentasaccharide that binds to antithrombin with high affinity. ...Finally, in patients with AF …
Emerging anticoagulants.
Kennedy B, Gargoum FS, Kennedy L, Khan F, Curran DR, O'Connor TM. Kennedy B, et al. Curr Med Chem. 2012;19(20):3388-416. doi: 10.2174/092986712801215847. Curr Med Chem. 2012. PMID: 22680641 Review.
Examples of indirect factor Xa inhibitors include fondaparinux, idraparinux and idrabiotaparinux. Direct thrombin inhibitors (factor IIa inhibitors) were developed with the limitations of standard heparin and warfarin in mind. ...
Examples of indirect factor Xa inhibitors include fondaparinux, idraparinux and idrabiotaparinux. Direct thrombin inhibitors (factor …
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
Harenberg J. Harenberg J. Thromb Haemost. 2009 Nov;102(5):811-5. doi: 10.1160/TH09-08-0555. Thromb Haemost. 2009. PMID: 19888513 Review.
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. ...Due to major bleeding events during treatment for more than six months the development of idraparinux was stopped. Idrabiotaparinux has an attached biotin moiety at the non-red …
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. ...Due to major bleeding events during treatme …
[New antitoagulants].
Samama MM, Gerotziafas G. Samama MM, et al. Ann Pharm Fr. 2007 Mar;65(2):85-94. doi: 10.1016/s0003-4509(07)90021-8. Ann Pharm Fr. 2007. PMID: 17404541 French.
The main characteristics of the new agents are: their site of action in the coagulation cascade and their mechanism of action which is indirect, antithrombin dependent, most often such as Fondaparinux and Idraparinux or direct such as Dabigatran, Rivaroxaban; the specifici …
The main characteristics of the new agents are: their site of action in the coagulation cascade and their mechanism of action which is indir …
New anticoagulants.
Weitz JI, Bates SM. Weitz JI, et al. J Thromb Haemost. 2005 Aug;3(8):1843-53. doi: 10.1111/j.1538-7836.2005.01374.x. J Thromb Haemost. 2005. PMID: 16102051 Free article. Review.
Fondaparinux, the first synthetic pentasaccharide, is licensed for prevention of venous thromboembolism (VTE) after major orthopedic surgery and for initial treatment of patients with VTE. Idraparinux, a long-acting pentasaccharide that is administered subcutaneously once- …
Fondaparinux, the first synthetic pentasaccharide, is licensed for prevention of venous thromboembolism (VTE) after major orthopedic surgery …
174 results